Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00516412
Recruitment Status : Completed
First Posted : August 15, 2007
Last Update Posted : September 29, 2015
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research